• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Apollo Endosurgery

FDA warns on over-inflation, pancreatitis risks with ReShape, Apollo intragastric balloons

February 9, 2017 By Fink Densford

The FDA today warned of potential risks associated with fluid-filled intragastric balloons, produced by ReShape Medical and Apollo Endosurgery, which are used to treat obesity. The federal watchdog said it has received multiple reports of 2 different types of adverse events associated with the balloons, including over-inflation requiring premature removal and the development of acute […]

Filed Under: Food & Drug Administration (FDA), Weight loss Tagged With: Apollo Endosurgery, ReShape Lifesciences

Smith & Nephew pulls the trigger on planned CFO succession | Personnel Moves | January 20, 2017

January 20, 2017 By Brad Perriello

Smith & Nephew (NYSE:SNN) said last week that CFO Julie Brown left the orthopedics & wound care company, after announcing her succession last July. Brown was named finance chief in November 2012 and assumed the role in February the following year. She is moving on to work as chief operating & financial officer for British luxury brand […]

Filed Under: Business/Financial News Tagged With: Apollo Endosurgery, Biolase, Endologix, Fresenius, Hologic, IsoRay, Merrimack Pharmaceuticals, Personnel Moves, Presbia, Smith & Nephew, SurgaColl

Apollo Endosurgery, Lpath close reverse merger

December 30, 2016 By Brad Perriello

Apollo Endosurgery and Lpath (NSDQ:LPTN) said yesterday that they closed a reverse merger in which Apollo put another $29 million into the combined company. Shares in the new company, which will adopt the Apollo Endosurgery name, are slated to begin trading today on the NASDAQ exchange under the APEN symbol. After a 1-for-5.5-share reverse split, there are about 10.7 […]

Filed Under: Endoscopic, Mergers & Acquisitions, Wall Street Beat Tagged With: Apollo Endosurgery, Lpath

Apollo Endosurgery, Lpath ink reverse merger

September 9, 2016 By Brad Perriello

Apollo Endosurgery and Lpath Inc. (NSDQ:LPTN) said yesterday that they inked a reverse merger agreement that will see Apollo’s owners become majority owners of the pharmaceutical company. Apollo plans to put another $29 million into the combined company, which will adopt the Apollo Endosurgery name, but apply for a new Nasdaq ticker symbol. The investment will form part […]

Filed Under: Business/Financial News, Mergers & Acquisitions, Weight loss Tagged With: Apollo Endosurgery, Lpath

Apollo taps Zillion for Orbera patient app

May 20, 2016 By Fink Densford

Apollo Endosurgery said it picked software application platform developer Zillion to support its Orbera Coach program, which is designed to provide virtual aftercare support for patients undergoing Orbera gastric balloon weight loss procedures. Through the program, which is powered by Zillion’s digital health platform, Orbera patients can access personally tailored 12-month programs designed to develop healthy […]

Filed Under: Patient Monitoring, Software / IT Tagged With: Apollo Endosurgery

For Apollo Endosurgery, a bet on older Allergan tech starts paying off

September 21, 2015 By Mark Hollmer

Apollo Endosurgery spent $90 million-plus nearly two years ago to acquire the Lap-Band gastric band weight loss system and the in-development Orbera intra-gastric balloon from Allergan (NYSE: AGN). A well-trained, international sales force also came with the acquisition. Recently, I asked founder, president & chief commercial officer Dennis McWilliams if the investment was worth it, […]

Filed Under: Blog, Weight loss Tagged With: Allergan, Apollo Endosurgery

Apollo Endosurgery wins FDA nod for gastric weightloss balloon

August 6, 2015 By Fink Densford

Apollo Endosurgery said today it won FDA pre-market approval for its weight-loss focused Orbera intragastric balloon. The balloon device is designed to be inserted non-surgically in obese patients with body mass indexes of 30 to 40, the Austin, Texas-based company said. After insertion, the balloon is inflated to fill space in the stomach. “While new […]

Filed Under: Food & Drug Administration (FDA), Regulatory/Compliance, Weight loss Tagged With: Apollo Endosurgery

Sharma out, Heinick in as Calhoun Vision CEO | Personnel Moves

March 20, 2015 By Brad Perriello Leave a Comment

Sharma out, Heinick in as Calhoun Vision CEO | Personnel Moves

Filed Under: News Well Tagged With: Agilent Technologies Inc., Apollo Endosurgery, Calhoun Vision, ConMed Corp., Endologix, Hillrom, Insulet, mazorrobotics, OCTANe, Personnel Moves, Spectranetics Corp.

Apollo Endosurgery secures $50m loan

March 11, 2015 By Val Kennedy Leave a Comment

Apollo Endosurgery secures $50m loan

Apollo Endosurgery said it secured a $50 million term loan from Athyrium Capital Management it plans to use to refinance its debt.

Filed Under: Funding Roundup, News Well Tagged With: Apollo Endosurgery, Bariatrics, Debt Financing

Obesity: Allergan finalizes Lap-Band division sale

December 3, 2013 By Arezu Sarvestani Leave a Comment

Allergan finalizes Lap-Band division sale

Medtech company Allergan (NYSE:AGN) officially dumped its obesity interventions business, consummating with Apollo Endosurgery a deal worth up to $110 million.

Filed Under: Mergers & Acquisitions, News Well, Weight loss Tagged With: Allergan, Apollo Endosurgery, Bariatrics

Apollo Endosurgery to buy Allergan’s obesity biz for up to $110M

October 29, 2013 By Brad Perriello Leave a Comment

Apollo Endosurgery to buy Allergan's obesity biz for up to $110M

Almost exactly 1 year after saying it would seek a buyer for its Lap-Band obesity device, Allergan (NYSE:AGN) said today that Apollo Endosurgery agreed to spend up to $110 million on Allergan’s obesity intervention business, which includes the Orbera intra-gastric balloon.

Filed Under: Mergers & Acquisitions, News Well, Weight loss Tagged With: Allergan, Apollo Endosurgery, Bariatrics

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS